Patents Assigned to Cellectis
  • Patent number: 12012607
    Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: June 18, 2024
    Assignee: Cellectis
    Inventors: Nicholas Baltes, Javier Gil Humanes
  • Patent number: 11959091
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 16, 2024
    Assignee: Cellectis
    Inventors: Philippe Duchateau, André Choulika, Laurent Poirot
  • Patent number: 11944643
    Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 2, 2024
    Assignee: CELLECTIS SA
    Inventors: Julianne Smith, Philippe Duchateau, Murielle Derrien
  • Publication number: 20240076685
    Abstract: Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein. For example, a Brassica plant, plant part, or plant cell having an induced mutation in one or more FAD2 gene copies, oil produced from the plant, plant part, or plant cell has increased oleic acid content and decreased linolenic acid content as compared to oil produced from a corresponding wild type Brassica plant, plant part, or plant cell, wherein the mutation was induced by one or more rare cutting endonucleases targeted to the one or more FAD2 gene copies, and methods of making and using the Brassica plant, plant part or plant cell, are provided.
    Type: Application
    Filed: April 10, 2023
    Publication date: March 7, 2024
    Applicant: CELLECTIS
    Inventors: Wenzheng Zhang, Feng Zhang
  • Patent number: 11919961
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 5, 2024
    Assignee: CELLECTIS
    Inventor: Roman Galetto
  • Patent number: 11903968
    Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: February 20, 2024
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Anne-Sophie Gautron, Laurent Poirot, Julien Valton
  • Patent number: 11891614
    Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 17, 2020
    Date of Patent: February 6, 2024
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Publication number: 20240026376
    Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism.
    Type: Application
    Filed: October 4, 2023
    Publication date: January 25, 2024
    Applicant: CELLECTIS
    Inventors: Laurent POIROT, David SOURDIVE, Philippe DUCHATEAU, Jean-Pierre CABANIOLS
  • Patent number: 11873511
    Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: January 16, 2024
    Assignee: CELLECTIS
    Inventors: Brian Busser, Philippe Duchateau, Alexandre Juillerat, Laurent Poirot, Julien Valton
  • Patent number: 11820996
    Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: November 21, 2023
    Assignee: CELLECTIS
    Inventors: Laurent Poirot, David Sourdive, Philippe Duchateau, Jean-Pierre Cabaniols
  • Publication number: 20230357719
    Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSI or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
    Type: Application
    Filed: May 22, 2023
    Publication date: November 9, 2023
    Applicant: Cellectis
    Inventors: Philippe DUCHATEAU, Laurent POIROT
  • Patent number: 11778993
    Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. The present invention also concerns methods to use these proteins. The present invention also relates to vectors, compositions and kits in which RVD domains and Transcription Activator-Like Effector (TALE) proteins of the present invention are used.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 10, 2023
    Assignee: CELLECTIS, S.A.
    Inventors: Philippe Duchateau, Alexandre Juillerat, Claudia Bertonati
  • Patent number: 11767512
    Abstract: The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 26, 2023
    Assignees: CELLECTIS, ALBERT-LUDWIGS-UNIVERSITAT FREIBURG
    Inventors: Toni Cathomen, Tatjana Cornu, Philippe Duchateau, Claudio Mussolino, Marianna Romito, Agnes Gouble
  • Patent number: 11690873
    Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 4, 2023
    Assignee: CELLECTIS SA
    Inventors: Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
  • Patent number: 11692169
    Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: July 4, 2023
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Laurent Poirot
  • Publication number: 20230201260
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 29, 2023
    Applicant: CELLECTIS
    Inventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
  • Patent number: 11685935
    Abstract: The present invention is in the field of CRISPR-Cas system for genome targeting. The present invention relates to new engineered Cas9 scaffolds and uses thereof. More particularly, the present invention relates to methods for genome targeting, cell engineering and therapeutic application. The present invention also relates to vectors, compositions and kits in which the new Cas9 scaffolds of the present invention are used.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 27, 2023
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Claudia Bertonati
  • Patent number: 11674155
    Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: June 13, 2023
    Assignee: CELLECTIS
    Inventors: Jean-Pierre Cabaniols, Jean-Charles Epinat, Philippe Duchateau
  • Patent number: 11624072
    Abstract: Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: April 11, 2023
    Assignee: Cellectis
    Inventors: Wenzheng Zhang, Feng Zhang
  • Patent number: 11603539
    Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 14, 2023
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith